Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-07-01
2008-09-09
Chen, Stacy B. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S204100
Reexamination Certificate
active
07423138
ABSTRACT:
By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2ad/dbprotein, either directly or by gene transfer techniques, to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.
REFERENCES:
patent: 5219990 (1993-06-01), Androphy et al.
patent: 5576206 (1996-11-01), Schlegel
patent: 5656599 (1997-08-01), Androphy et al.
patent: 5667965 (1997-09-01), Androphy et al.
patent: 5744133 (1998-04-01), Lathe et al.
patent: 5888516 (1999-03-01), Jansen et al.
patent: 0 302 758 (1989-02-01), None
patent: 0 302 758 (1989-02-01), None
patent: WO 91/15580 (1991-10-01), None
patent: WO 92/12728 (1992-08-01), None
Goodwin et al., Repression of human papillomavirus oncogenes, PNAS, 2000, 97(23):12513-12518.
Androphy, E. et al., “Bovine Papillomavirus E2 Trans-activating Gene Product Binds to Specific Sites in Papillomavirus DNA,”Nature, 325:70-73 (1987).
Barsoum, J. et al., “Mechanism of Action of the Papillomavirus E2 Repressor: Repression in the Absence of DNA Binding,”J. Virol., 66:3941-3945 (1992);
Bouvard et al. (1994) “Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes”The Embo Journal, 13(22):5451-5459.
Choe, J. et al., “Bovine Papillomavirus Type 1 Encodes Two Forms of a Transcriptional Repressor: Structural and Functional Analysis of New Viral cDNAs,”J. Virol., 63:1743-1755 (1989).
Dartmann, K. et al., “Short Communications,”Virology, 151:124-30 (1986).
Dostani, N. et al., “The Functional BPV-1 E2 Trans-activating Protein can Act as a Repressor by Preventing Formation of the Initiation Complex,”Genes&Dev., 5:1657-1671 (1991).
Dulic, V. et al., “Altered Regulation of G1Cyclins in Senescent Human Diploid Fibroblasts: Accumulation of Inactive Cyclin E-Cdk2 and Cyclin D1-Cdk2 Complexes,”Proc. Natl. Acad. Sci. USA, 90:11034-11038 (1993).
Giri, I. and Yaniv, M., “Structural and Mutational Analysis of E2 Trans-activating Proteins of Papillomaviruses Reveals Three Distinct Functional Domains,”EMBO J., 7:2823-29 (1988).
Gloss, B. and Bernard, H., “The E6/E7 Promoter of Human Papillomavirus Type 16 is Activated in the Absence of E2 Proteins by a Sequence-Aberrant Sp1 Distal Element,”J. Virology, 64:5577-5584 (1990).
Hawley-Nelson, P. et al., “The Specific DNA Recognition Sequence of the Bovine Papillomavirus E2 Protein is and E2-dependent Enhancer,”EMBO J., 7:525-31 (1988).
Hirochika, H. et al., “Enhancers and Trans-Acting E2 Transcriptional Factors of Papillomaviruses,”J. Virol., 61:2599-606 (1987).
Hwang, E. et al., “Inhibition of Cervical Carcinoma Cell Line Proliferation by the Introduction of a Bovine Papillomavirus Regulatory Gene,”J. Virol., 67:3720-3729 (1993).
Lambert, P. et al., “A Transcriptional Repressor Encoded by BPV-1 Shares a Common Carboxy-Terminal Domain with the E2 Transactivator,”Cell, 50:69-78 (1987).
Li, R., et al., “Specific Recognition Nucleotides and Their DNA Context Determine the Affinity of E2 Protein for 17 Binding Sites in the BPV-1 Genome,”Genes&Dev., 3:510-526 (1989).
Matsushime, H. et al., “D-Type Cyclin-Dependent Kinase Activity in Mammalian Cells,”Mol. Cell Biol., 14:2066-2076 (1994).
McBride, A. et al., “Phosphorylation Sites of the E2 Transcriptional Regulatory Proteins of Bovine Papillomavirus Type 1,”J. Virol., 63:5076-5085 (1989).
McBride, A. et al., “The Papillomavirus E2 Regulatory Proteins,”J. Biol Chem., 266:18411-18414 (1991).
Mohr, I. et al., “Targeting the E1 Replication Protein to the Papillomavirus Origin of Replication by Complex Formation with the E2 Transactivator,”Science, 250:1654-99 (1990).
Romanczuk, H. et al., “Mutational Analysis of cis Elements Involved in E2 Modulation of Human Papillomavirus Type 16 P97and Type 18 P105Promoters,”J. Virol., 64:2849-2859 (1990).
Sousa, R. et al., “Control of Papillomavirus Gene Expression,”Biochemica et Biophysica Acta, 1032:19-37 (1990).
Spalholz, B. et al., “Characterization of the cis Elements Involved in Basal and E2-Transactivated Expression of the Bovine Papillomavirus P2443Promoter,”J. Virol., 65:743-753 (1991).
Stenlund, A. and Botchan, M., “The E2 Trans-Activator can act as a Repressor by Interfering with a Cellular Transcription Factor,”Genes&Dev., 4:123-136 (1990).
Thierry, F. and Howley, P., “Functional Analysis of E2-Mediated Repression of the HPV18P105Promoter,”The New Biol., 3:90-100 (1991).
Vande Pol, S. and Howley, P., “A Bovine Papillomavirus Constitutive Enhancer is Negatively Regulated by the E2 Repressor Through Competitive Binding for a Cellular Factor,”J. Virol., 64:5420-5429 (1990).
Winokur, P. and McBride, A., “Separation of the Transcriptional Activation and Replication Functions of the Bovine Papillomavirus-1 E2 Protein,”EMBO J., 11:4111-4118 (1992).
Benson, John. D. et al., “Amino-Terminal Domains of the Bovine Papillomavirus Type 1 E1 and E2 Proteins Participate in Complex Formation,”J. Virology69(7):4364-4372 (1995).
Benson, John D. et al., “Conserved Interaction of the Papillomavirus E2 Transcriptional Activator Proteins with Human and Yeast TFIIB Proteins,”J. Virology71(10):8041-8047 (1997).
Ferguson, Mary K et al., “Genetic Analysis of the Activation Domain of Bovine Papillomavirus Protein E2: Its Role in Transcription and Replication,”J. Virology70(7):4193-4199 (1996).
Goodwin, Edward C. et al., “Transactivation-Competent Bovine Papillomavirus E2 Protein Is Specifically Required for Efficient Repression of Human Papillomavirus Oncogene Expression and for Acute Growth Inhibition of Cervical Carcinoma Cell Lines,”J. Virology72(5):3925-3934 (1998).
Kasukawa, Hiroaki et al., “A Fifteen-Amino-Acid Peptide Inhibits Human Papillomavirus E1-E2 Interaction and Human Papillomavirus DNA Replication In Vitro,”J. Virology72(10):8166-8173 (1998).
Phelps, W. C. et al., “Molecular targets for human papillomaviruses: prospects for antiviral therapy,”Antiviral Chemistry&Chemotherapy9:359-377 (1998).
Sakai, Hiroyuki et al., “Targeted Mutagenesis of the Human Papillomavirus Type 16 E2 Transactivation Domain Reveals Separable Transcriptional Activation and DNA Replicaiton Functions,”J. Virology70(3):1602-1611 (1996).
Yasugi, Toshiharu et al., “Mapping and Characterization of the Interaction Domains of Human Papillomavirus Type 16 E1 and E2 Proteins,”J. Virology71(2):891-899 (1997).
Yasugi, Toshiharu et al., “Two Classes of Human Papillomavirus Type 16 E1 Mutants Suggest Pleiotropic Conformational Constraints Affecting E1 Multimerization, E2 Interaction, and Interaction with Cellular Proteins,”J. Virology71(8):5942-5951 (1997).
Crystal, Ronald G., “Transfer of genes to humans: early lessons and obstacles to success,”Science270:404-410 (1995).
Mastrangelo et al., “Gene therapy for human cancer: an essay for clinicians,” Seminars inOncology23(1): 4-21 (1996).
Androphy, E. et al.., “Bovine Papillomavirus E2 Trans-activating Gene Product Binds to Specific Sites in Papillomavirus DNA,”Nature, 325:70-73 (1987).
Barsoum, J. et al.., “Mechanism of Action of the Papillomavirus E2 Repressor: Repression in the Absence of DNA Binding,”J. Virol., 66:3941-3945 (1992).
Benson, John D. et al.., “Conserved Interaction of the Papillomavirus E2 Transcriptional Activator Proteins with Human and Yeast TFIIB Proteins
Benson John D.
Dowhanick-Morrissette Jennifer J.
Howley Peter M.
Sakai Hiroyuki
Chen Stacy B.
Gorny Sloper Jill
Lahive & Cockfield LLP
President and Fellows of Harvard College
Williams Megan E.
LandOfFree
Compositions and methods for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974542